Vaccine: X最新文献

{"title":"Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study","authors":"Sitthichai Kanokudom ,&nbsp;Jira Chansaenroj ,&nbsp;Nungruthai Suntronwong ,&nbsp;Lakkhana Wongsrisang ,&nbsp;Ratchadawan Aeemjinda ,&nbsp;Preeyaporn Vichaiwattana ,&nbsp;Thaksaporn Thatsanathorn ,&nbsp;Warangkana Chantima ,&nbsp;Pattarakul Pakchotanon ,&nbsp;Thaneeya Duangchinda ,&nbsp;Natthinee Sudhinaraset ,&nbsp;Sittisak Honsawek ,&nbsp;Yong Poovorawan","doi":"10.1016/j.jvacx.2024.100538","DOIUrl":"10.1016/j.jvacx.2024.100538","url":null,"abstract":"<div><p>This cohort study, conducted between July and August 2023, evaluated the adverse events (AEs) and immune response to a bivalent mRNA-1273.222 (containing sequences of the original Wuhan-H1 strain and the Omicron BA.4/5 variant) booster vaccine in 122 participants. The study included individuals with diverse vaccination histories, and their responses were assessed based on anti-receptor binding domain (RBD) IgG levels and neutralizing antibodies against the wild-type, Omicron BA.5, and XBB.1.16 variants. Following administration of the BA.4/5 bivalent vaccine, AEs were generally mild to moderate and well-tolerated within a few days. There were no reports of vomiting and no serious AEs or death. The findings demonstrated robust immune responses, with significant increases in anti-RBD IgG levels, particularly in groups that had received 3 –6 doses before the booster dose. The BA.4/5 bivalent booster effectively induced neutralizing antibodies against the vaccine strains, providing robust neutralization, including the XBB.1.16 strain. The study also highlighted that individuals with hybrid immunity, especially those assumed infected with the BA.5 strain or who had been infected twice, showed higher levels of robust neutralizing activity against Omicron XBB.1.16. Overall, these results indicate that the BA.4/5 bivalent booster vaccines can induce potent and good antibody responses in emerging Omicron subvariants, supporting its efficacy as a booster in individuals with diverse vaccination histories.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100538"},"PeriodicalIF":2.7,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001116/pdfft?md5=279b83a03fe8e2e3b75f37d89c1b39c0&pid=1-s2.0-S2590136224001116-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing vaccine hesitancy and vaccine literacy among the European prison population and staff: A multicentre observational study","authors":"D. Petri ,&nbsp;M. Fornili ,&nbsp;E. De Vita ,&nbsp;M.A. Malanima ,&nbsp;I. Yiasemi ,&nbsp;J. Mavrou ,&nbsp;T. Trattonikolas ,&nbsp;I. Stylianou ,&nbsp;F. Meroueh ,&nbsp;E. Murauer ,&nbsp;A. Mieuset ,&nbsp;R. Ranieri ,&nbsp;N. Cocco ,&nbsp;V. Busmachiu ,&nbsp;I. Barbirosh ,&nbsp;L. Tataru ,&nbsp;S. Doltu ,&nbsp;S. Mazzilli ,&nbsp;L. Tavoschi ,&nbsp;L. Baglietto","doi":"10.1016/j.jvacx.2024.100537","DOIUrl":"10.1016/j.jvacx.2024.100537","url":null,"abstract":"<div><p>Vaccination is the most efficient and cost-effective public health intervention. Prison population, for its low social distancing, constant turnover, and high percentage of migrants, should be an important target of vaccination campaign. However, vaccination coverage in prison is low. In this study we estimated vaccine hesitancy and vaccine literacy among the prison population and staff and assessed their correlation.</p><p>We conducted a cross-sectional study in 13 prisons of 4 European countries. The sample included 847 people living in prison and 755 staff members. Through a structured questionnaire we assessed vaccine hesitancy, vaccine literacy, general health literacy, previous vaccine refusal and socio-demographic characteristics of participants. Exploratory factor analysis was used to extract three components of vaccine hesitancy. Logistic regression was applied to assess the association between previous vaccine refusal and vaccine hesitancy; linear regression was applied to assess the association between vaccine hesitancy and vaccine and general health literacy. All analyses were adjusted for socio-demographic variables.</p><p>We identified three components of vaccine hesitancy explaining 49% of the total variance: <em>Mistrust</em>, <em>Concern</em> and <em>Conspiracy</em>. In both people living in prison and staff, all the components were associated to previous vaccine refusal (p-value &lt; 0.001) and presented good internal consistency (Cronbach’s alpha = 0.90, 0.73 and 0.78). Young participants presented the highest levels of vaccine hesitancy; migrant people living in prison had the lower levels of <em>Mistrust</em> and the higher level of <em>Concern</em>; all three factors were lower among participants with the highest degree of education. <em>Mistrust</em> and <em>Concern</em> were inversely associated with vaccine literacy while all three subscales were inversely associated with general health literacy (all p-values &lt; 0.001).</p><p>This study suggests that educational interventions aimed at increasing vaccine literacy in people living and working in prison could decrease vaccine hesitation and consequently increase vaccination uptake among the prison population and staff.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100537"},"PeriodicalIF":2.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001104/pdfft?md5=f3434b6dfe20d2ef216e493a273f5d9c&pid=1-s2.0-S2590136224001104-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study","authors":"Anan Bzami,&nbsp;Changcheng Zhu,&nbsp;Marcus Estrada,&nbsp;Jessica A. White,&nbsp;Manjari Lal","doi":"10.1016/j.jvacx.2024.100535","DOIUrl":"10.1016/j.jvacx.2024.100535","url":null,"abstract":"<div><p>Current lead coronavirus vaccines require continuous cold or ultra-cold storage from the manufacturing site to the field to maintain protective efficacy. Since cold chain capacity is limited and complex, logistics planning is crucial to limit vaccine wastage.[1] The restrictive storage concerns also make it difficult to share vaccines between public health departments and neighboring states, leading to increased vaccine wastage.[2] A Newcastle Disease Virus (NDV) vector-based severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccine candidate, NDV-HXP-S, offers a cost-effective alternative which aims to improve global access to SARS CoV-2 vaccines.[3] The NDV-HXP-S vaccine candidate can be mass-produced in chicken eggs and has demonstrated efficacy in preclinical studies, as well as acceptable safety and<!--> <!-->potent immunogenicity in clinical studies.[3,4–10] To further advance the NDV-HXP-S vaccine candidate, this manuscript describes work focused on the development of multidose thermotolerant vaccine formulations (i.e., those which would not require continuous extended<!--> <!-->refrigeration), making it convenient to use and store, and simplifying transport and distribution logistics, especially in outbreak settings. Liquid and lyophilized formulations for parenteral administration were rigorously screened for the vaccine formulation’s ability to maintain S-antigen stability after exposure to temperature<!--> <!-->stress at 40 °C, 25 °C, and 2 °C to 8 °C storage for six months. Preservative efficacy was evaluated to enable a multidose liquid vaccine format as well as endotoxin testing in lyophilized formulations. Lead liquid vaccine formations were identified that were able to maintain S-antigen content at 2 °C to 8 °C and 25 °C storage for the entire six-month study. Lead lyophilized vaccine formulations were identified which were able to maintain S-antigen content for six months at 2 °C to 8 °C, 25 °C, and 40 °C. Both the liquid and lyophilized formulations identified are improved thermotolerant SARS-CoV-2 vaccine formulations.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100535"},"PeriodicalIF":2.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001086/pdfft?md5=9c8e3409bd752b317ceaec848e64544b&pid=1-s2.0-S2590136224001086-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141840690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of costs of human papillomavirus vaccine delivery in six low- and middle-income countries","authors":"Mercy Mvundura ,&nbsp;Rose Slavkovsky ,&nbsp;Frédéric Debellut ,&nbsp;Teddy Naddumba ,&nbsp;Clint Pecenka ,&nbsp;D. Scott Lamontagne ,&nbsp;HPV vaccine cost of delivery study collaborators","doi":"10.1016/j.jvacx.2024.100534","DOIUrl":"10.1016/j.jvacx.2024.100534","url":null,"abstract":"<div><p>Evidence on determinants of vaccine delivery costs can inform program design and planning. Given the dearth of this evidence for human papillomavirus (HPV) vaccine, we conducted an analysis to identify programmatic and operational factors that are statistically associated with variations in economic costs for HPV vaccine delivery, within and across six low- and middle-income countries.</p><p>HPV vaccine program operations and cost data were collected from Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda. An ordinary least square regression analysis was done using data from 279 health facilities in these six countries. We ran country-specific and pooled multivariate linear regressions. A conditional regression including 228 facilities was also run. The dependent variable was the estimated total economic costs for HPV vaccine delivery per facility, excluding vaccine procurement costs. Explanatory variables included number of HPV vaccine doses delivered; numbers of vaccination sessions conducted, and schools served; distance traveled by health workers for vaccine delivery; intensity of conducting program activities; human resource (health workers, school staff, etc.) utilization rates; and categorical variables indicating whether per diems were paid, and for country-specific dummies;</p><p>Explanatory variables such as the number of program activities or meetings held, receipt of per diems, and utilization rates of health workers, were all positively and statistically significantly associated with economic costs in the pooled sample, for both the unconditional and conditional regressions. Variables such as the doses delivered, and number of sessions conducted were statistically significant in the unconditional regression. The within-country regression found that only variations in utilization rates of health workers were statistically significant in all countries.</p><p>Our analysis provides evidence to HPV vaccination program stakeholders on which program context variables impact costs, which can inform program adjustment to improve cost efficiency, especially as programs managers work to revitalize and rebuild HPV vaccine coverage after the COVID-19 pandemic.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100534"},"PeriodicalIF":2.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001074/pdfft?md5=e84b21297f8a099684dddbed1469bd27&pid=1-s2.0-S2590136224001074-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of maternal infection of SARS-CoV-2 and neonatal susceptibility: A retrospective cohort study","authors":"Xiao-Dan Zhu ,&nbsp;Yan-Jie Peng ,&nbsp;Ying Chen ,&nbsp;Mei Xue ,&nbsp;Ai-Juan Zhang ,&nbsp;Yu Peng ,&nbsp;Rong Mei ,&nbsp;Mei-Rong Tian ,&nbsp;Lin Zhang","doi":"10.1016/j.jvacx.2024.100536","DOIUrl":"10.1016/j.jvacx.2024.100536","url":null,"abstract":"<div><h3>Objective</h3><p>This study aims to assess the risk of neonatal susceptibility to COVID-19 among pregnant women.</p></div><div><h3>Methods</h3><p>We conducted a retrospective cohort study involving 1089 pregnant women ≥28 weeks of gestational age, who were categorized into infected and uninfected groups. Data for all participants were collected through a comprehensive review of electronic medical records and follow-up phone calls. The primary outcome was neonatal infection with SARS-CoV-2, while secondary outcomes included delivery patterns and gestational age at delivery.</p></div><div><h3>Results</h3><p>Maternal vaccination (OR 95%CI:0.63[0.46, 0.85]) and maternal infection with SARS-CoV-2 (OR 95%CI: 0.45[0.34, 0.60]) were found to be associated with a decreased risk of neonatal infection. The infected group exhibited a lower neonatal SARS-CoV-2 infection rate (25.93%) compared to the uninfected group (45.15%). Logistic regression analysis identified several risk factors associated with an increased risk of neonatal infection, including pregnancy BMI (OR 95%CI: 1.04[1.01, 1.08]), age at first pregnancy (OR 95%CI: 1.05[1.01, 1.10]), age at menarche (OR 95%CI: 1.13[1.02, 1.26]), and parturition (Yes vs. No) (OR 95%CI:1.4 [1.04,1.88]).</p></div><div><h3>Conclusion</h3><p>Maternal vaccination and perinatal infection with SARS-CoV-2 play a protective role in preventing neonatal SARS-CoV-2 infection.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100536"},"PeriodicalIF":2.7,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001098/pdfft?md5=b53caa3833291a0050b60e1a2ab26e36&pid=1-s2.0-S2590136224001098-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary provider perspectives on how to address HPV vaccine hesitancy in the US: A qualitative study","authors":"Anna L. Beavis ,&nbsp;Mahima S. Krishnamoorthi ,&nbsp;Sarah Adler ,&nbsp;Laura G. Fleszar ,&nbsp;Meghan B. Moran ,&nbsp;Anne F. Rositch","doi":"10.1016/j.jvacx.2024.100533","DOIUrl":"10.1016/j.jvacx.2024.100533","url":null,"abstract":"<div><h3>Introduction</h3><p>Despite over 15 years of real-world data that supports the safety and efficacy of the human papillomavirus (HPV) vaccine, in the United States vaccine hesitancy persists. Many studies have focused on vaccine-hesitant parents, but fewer have examined provider perspectives on how to address HPV vaccine hesitancy.</p></div><div><h3>Methods</h3><p>Between July 2021-April 2022, we recruited providers in Maryland and the broader Mid-Atlantic region who practiced pediatrics, primary care, family medicine, or adolescent medicine and who provided outpatient care for children ages 10–17. Semi-structured virtual interviews focused on provider-reported strategies to address HPV vaccine-hesitant parents, as well as perceived barriers to successful vaccination and provider perspectives on specific interventions to address parental hesitancy. Audio recordings were transcribed and analyzed via a combination of deductive and inductive coding.<!--> <!-->Higher-level themes within the domains of strategies, barriers, and perspectives on specific proposed interventions were identified.</p></div><div><h3>Results and discussion</h3><p>A total of sixteen providers completed an interview. Within the domain of provider-reported strategies, the following themes emerged: 1) leveraging continuity of care and established parental trust, 2) supporting parental autonomy, 3) tailoring the approach to specific concerns of vaccine-hesitant parents, 4) normalizing the HPV vaccine, and 5) focusing on health prevention and cancer prevention. Barriers providers identified were: 1) limited time, 2) lack of common ground with parents, 3) parent–child decision discordance, 4) availability of misinformation, and 5) parental concerns such as safety and necessity. In the domain for proposed interventions, providers favored interventions that saved time or were not resource-intense, that did not single out the HPV vaccine as different, were patient friendly, and leveraged efficiency through the electronic medical record. The insights from this study can help inform the development of provider-acceptable and feasible tools and interventions to address parental HPV vaccine hesitancy.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"20 ","pages":"Article 100533"},"PeriodicalIF":2.7,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001062/pdfft?md5=8a419ba11801fadaa90935875bfc01ec&pid=1-s2.0-S2590136224001062-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active offer of Tdap vaccination in a cohort of healthcare workers of Maternal and Neonatal Department: Data from a large hospital in Southern Italy","authors":"Antonio Di Lorenzo ,&nbsp;Luca Capodiferro ,&nbsp;Michele Illuzzi ,&nbsp;Chiara Scaltrito ,&nbsp;Luigi Vimercati ,&nbsp;Lorenza Moscara ,&nbsp;Silvio Tafuri ,&nbsp;Pasquale Stefanizzi","doi":"10.1016/j.jvacx.2024.100530","DOIUrl":"10.1016/j.jvacx.2024.100530","url":null,"abstract":"<div><p>Pertussis is a vaccine-preventable respiratory disease. Pertussis vaccination is currently mandatory for all children in Italy, and is administered in three doses at the beginning of the third, fifth, and twelfth month of life, respectively. Booster doses are also recommended at five-six years, at eleven-twelve years, and then once every ten years. Healthcare workers (HCWs) are a high-risk population for pertussis. Strategies to increase HCWs’ compliance to this vaccination have not been investigated in depth. Our study investigates the determinants of acceptance of a “soft nudge” vaccination campaign in a large hospital in Apulia (Southern Italy).</p><p>HCWs from the Gynaecology and Neonatology Units of Bari’s Policlinico General Hospital were screened in June 2023 for pertussis vaccination. Non-vaccinated subjects were offered a vaccination appointment. Vaccination determinants were studied, and a logistic regression model was built to identify determinants that significantly influence vaccination acceptance.</p><p>At the time of screening, only 31.34% of target HCWs (68/217) had already been vaccinated. After the active call intervention, vaccine coverage rose to 70.00% (152/217). Significantly higher coverage was found in the Neonatology Unit (30/43, 69.77%) than in the Gynaecology unit (54/106, 50.94%) (Chi2: 4.41; p-value: 0.036). A logistic regression model confirmed a higher compliance to vaccination in HCWs staffed in the Neonatology Unit (Chi2: 2.08; 95%CI: 1.04 – 4.73; p-value: 0.038).</p><p>Our intervention increased vaccination coverage in a high-risk cohort. The solicitation was effective, as communication with a trained specialist might have improved the subjects’ perception of vaccination and individual risk of contagion and transmission to others. A synergistic approach, mixing active call with a vaccination mandate, might have greater effectiveness.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100530"},"PeriodicalIF":2.7,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224001037/pdfft?md5=0f80e4a5fd7dc9a04acf2c6909041cf0&pid=1-s2.0-S2590136224001037-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141728758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HTLV-1 vaccination Landscape: Current developments and challenges","authors":"Arash Letafati ,&nbsp;Mahshid Bahari ,&nbsp;Omid Salahi Ardekani ,&nbsp;Negar Nayerain Jazi ,&nbsp;Abuzar Nikzad ,&nbsp;Farnaz norouzi ,&nbsp;Bahar Mahdavi ,&nbsp;Amir Aboofazeli ,&nbsp;Sayed-Hamidreza Mozhgani","doi":"10.1016/j.jvacx.2024.100525","DOIUrl":"10.1016/j.jvacx.2024.100525","url":null,"abstract":"<div><p>Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that is distinguished for its correlation to myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). As well, HTLV-1 has been documented to have links with other inflammatory diseases, such as uveitis and dermatitis. According to the World Health Organization (WHO), the global distribution of HTLV-1 infection is estimated to extend between 5 and 10 million individuals. Recent efforts in HTLV-1 vaccine development primarily involve selecting viral components, such as antigens, from structural and non-structural proteins. These components are chosen to trigger a vigorous immune response from cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs), and B cells. Investigation into developing a vaccine against HTLV-1 is ongoing, and current surveys have explored several approaches, including viral vector vaccines, DNA vaccines, protein and peptide vaccines, dendritic cell-based vaccines, mRNA vaccines, and other platforms. Despite these investigations have shown promising results, challenges like the necessity for long-term protective immunity, addressing viral diversity, and managing potential side effects remain. It is critical to keep track of the progress made in HTLV-1 vaccination research to comprehend the development status and its possible impacts. The evolving nature of vaccine development underscores the importance of staying informed about advancements as we strive to combat HTLV-1-associated diseases through effective vaccination strategies. In this review, our goal is to provide an overview of the current status of HTLV-1 vaccination efforts, emphasizing the progress, challenges, and potential future directions in this vital area of research.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100525"},"PeriodicalIF":2.7,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000986/pdfft?md5=b3f0c8931f01b16b16ced8b63021aa3a&pid=1-s2.0-S2590136224000986-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How stressful was the COVID-19 vaccination procedure? Comparison between mass vaccination centers and general practices","authors":"Anne Schrimpf,&nbsp;Anne Jentzsch,&nbsp;Markus Bleckwenn,&nbsp;Anne-Kathrin Geier","doi":"10.1016/j.jvacx.2024.100524","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100524","url":null,"abstract":"<div><p>Negative past experiences with vaccines or unfamiliar environments can be sources of stress during the COVID-19 vaccination procedure. We examined whether the perceived stressfulness of the vaccination procedure differ between mass vaccination centers and general practitioner (GP) practices. A survey was distributed (07/2021–10/2021) among newly vaccinated individuals in ten GP practices (n = 364) and two vaccine centers (n = 474). Stress was low at all sites. The perceived stressfulness of the procedure was higher among younger participants and those in GP practices, and increased with longer waiting time at the site. Stress decreased with better comprehensibility of the procedure and higher satisfaction with patient education. Participants who expressed greater concern about the health risks of COVID-19 vaccines perceived the vaccination procedure as more stressful. Our findings indicate opportunities for improvements in future vaccination campaigns and highlight the important role of healthcare providers in mitigating stress by addressing individual concerns.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100524"},"PeriodicalIF":2.7,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000974/pdfft?md5=e0420ff4ab0b12e33f18e12d9edc6c63&pid=1-s2.0-S2590136224000974-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of safety and adverse events following COVID-19 vaccination and their predictors in first 30 days among healthcare workers of a tertiary care teaching hospital in North India","authors":"MD. Abu Bashar ,&nbsp;Bhushan Kamble ,&nbsp;Sampath Kumar ,&nbsp;Sanket V. Nandekar ,&nbsp;Sharad Kumar Mathur","doi":"10.1016/j.jvacx.2024.100522","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100522","url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 vaccines were rolled out as an emergency measure, with an expedited approval to contain the pandemic. The objective of this study was to assess the incidence, pattern and severity of AEFIs reported following COVID-19 vaccination and their predictors among the healthcare workers.</p></div><div><h3>Materials and methods</h3><p>A prospective cohort study enrolling healthcare workers of a tertiary care Institute in North India receiving COVISHIELD™ from February to May 2021 was carried out to assess the incidence, pattern and severity of AEFI over the next 30 days. Both active and passive surveillance methods were used for AEFI recording. Bivariate analysis was performed to ascertain the predictors of AEFIs.</p></div><div><h3>Results</h3><p>A total of 836 healthcare workers who received the first dose of COVISHIELD™ were included in the study of which 201 (24.0 %) experienced one or more AEFIs. Majority of AEFIs were of minor grade (99.8 %) and resolved spontaneously. Majority (96.0 %) had onset of the AEFIs within 48 hrs of vaccination. Serious AEFIs, leading to hospitalization was noticed in 2(0.2 %) participants, both females, with suspicion of immunization stress related response (ISRR). Both of them recovered without any sequelae. No deaths were recorded. Factors found to be significantly associated with the occurrence of AEFIs in the participants were female gender (p = 0.02), monthly income &gt; 20,000 INR (p = 0.007), presence of any chronic illness (p &lt; 0.0001), history of allergic reaction to any drug/vaccine (p = 0.01), history of COVID-19 infection (p &lt; 0.00002) and history of hospitalization due to COVID-19 (p &lt; 0.0002).</p></div><div><h3>Conclusion</h3><p>Majority of the AEFIs observed were of minor grade with spontaneous resolution of the symptoms indicating safety and well tolerability of the vaccine. Female gender, higher income, history of allergy and co-morbidities, history of COVID-19 infection and history of hospitalization were found to be major predictors for the development of adverse events and require more watchful vaccination.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100522"},"PeriodicalIF":2.7,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000950/pdfft?md5=4d7aca639ec94655f77f1c27e43ec656&pid=1-s2.0-S2590136224000950-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}